Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice

BACKGROUND: Z-360 is an orally active cholecystokinin-2 (CCK2)/gastrin receptor antagonist currently under development as a therapeutic drug for pancreatic cancer. It was previously reported that Z-360 treatment in combination with gemcitabine prolonged the survival period in a lethal pancreatic can...

Descripción completa

Detalles Bibliográficos
Autores principales: Orikawa, Yuki, Kato, Hiroki, Seto, Koichi, Kobayashi, Nobuyoshi, Yoshinaga, Koji, Hamano, Hiroki, Hori, Yuko, Meyer, Tim, Takei, Mineo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2987997/
https://www.ncbi.nlm.nih.gov/pubmed/20979661
http://dx.doi.org/10.1186/1744-8069-6-72

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2987997/
https://www.ncbi.nlm.nih.gov/pubmed/20979661
http://dx.doi.org/10.1186/1744-8069-6-72

Ejemplares similares